[go: up one dir, main page]

Hajjar et al., 2022 - Google Patents

Selected Abstracts from the 13 th Annual Meeting of the Clinical Immunology Society: 2022 Annual Meeting: Immune Deficiency and Dysregulation North American …

Hajjar et al., 2022

View PDF
Document ID
7699309676606750203
Author
Hajjar J
Mendonca D
Conner M
Savidge T
Swennes A
Walter J
Petrosino J
Kheradmand F
Publication year
Publication venue
Journal of Clinical Immunology

External Links

Snippet

or NS 50μl, intraperitoneally (n= 4/group). D30 and D40 represent days 30 & 40 post-FMT, respectively. Principal coordinate analysis plots of unweighted distances of fecal microbiota generated by the 16S rRNA gene sequence analysis. Axis labels indicate the percentage of …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis

Similar Documents

Publication Publication Date Title
Charbonnier et al. Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked–like disorder caused by loss-of-function mutations in LRBA
Fijolek et al. Eosinophilic granulomatosis with polyangiitis–advances in pathogenesis, diagnosis, and treatment
Kelsen et al. North American Society for Pediatric Gastroenterology, Hepatology, and nutrition position paper on the evaluation and management for patients with very early‐onset inflammatory bowel disease
Rowczenio et al. Late-onset cryopyrin-associated periodic syndromes caused by somatic NLRP3 mosaicism—UK single center experience
Elgizouli et al. Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency
Gupta et al. Selective IgM deficiency—an underestimated primary immunodeficiency
Ammer-Herrmenau et al. Sepsis induces long-lasting impairments in CD4+ T-cell responses despite rapid numerical recovery of T-lymphocyte populations
Samuelson et al. Reduced B lymphoid kinase (Blk) expression enhances proinflammatory cytokine production and induces nephrosis in C57BL/6-lpr/lpr mice
KR20180004254A (en) Methods and compositions for the diagnosis and treatment of diseases in patients with high levels of CXCL9 and other biomarkers
Chen et al. The clinical features of autoimmunity in 53 patients with Wiskott–Aldrich syndrome in China: a single-center study
Al-Hakim et al. Improving diagnosis and clinical management of acquired systemic Autoinflammatory diseases
Cortesi et al. Unmasking inborn errors of immunity: identifying the red flags of immune dysregulation
Hajjar et al. Selected Abstracts from the 13 th Annual Meeting of the Clinical Immunology Society: 2022 Annual Meeting: Immune Deficiency and Dysregulation North American Conference
Anka et al. Biological and clinical significance of T helper 17 cell deficiency: insight into monogenic defects
Solimando et al. Inborn error of immunity: a journey through novel genes and clinical presentation
Chapoval et al. Requirements for allergen-induced airway inflammation and hyperreactivity in CD4-deficient and CD4-sufficient HLA-DQ transgenic mice
Yazdanpanah et al. Autoimmune disorders associated with common variable immunodeficiency: prediction, diagnosis, and treatment
Christine Rauscher et al. 2020 CIS Annual Meeting: Immune Deficiency & Dysregulation North American Conference
Letizia From Calcium signaling to Adipose tissue: Deciphering novel therapeutic targets for inflammatory bowel disease
Brodin et al. Inflammation and Immune Dysregulation in Inborn Errors of Immunity
Boz Caratterizzazione clinica, immunologica, genetica e trascrittomica delle Disregolazioni Immuni
Oktelik et al. DOCK8 deficiency due to a deep intronic variant in two kindreds with hyper-IgE syndrome
Mena Lucía Expression regulation and comparative interactome study of ANKRD55, a multiple sclerosis risk modulator
INHIBITS et al. 2017 CIS Annual Meeting: Immune Deficiency & Dysregulation North American Conference
Shadur Clinical and Cellular Response to Abatacept Therapy and Haematopoietic Stem Cell Transplantation in LRBA Deficiency